New PrismRA® blood test enables providers to identify optimal approach to rheumatoid arthritis treatment FEBRUARY 11, 2021 – WALTHAM, MA – Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced...
First-Of-Its-Kind Lab Test Helps Guide Targeted Treatment Decisions in Rheumatoid Arthritis FEBRUARY 3, 2021- WALTHAM, MA- Scipher Medicine, a precision immunology company matching patients with the most effective therapy, announced today they have partnered with...
Nine out of 10 responding rheumatologists stated the test would increase their confidence when making prescribing decisions WALTHAM, Mass. – DECEMBER 7, 2020Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today...
PrismRA® first-of-its-kind molecular signature test validated in Ambry’s central laboratory.Partnership provides infrastructure for rapid scaling and patient accessibility. SEPTEMBER 17, 2020- WALTHAM, MA, and ALISO VIEJO, CA – Scipher Medicine, a precision...
— Companies to jointly validate novel drug targets —- Scipher eligible for upfront, opt-in and milestone payments —- Galapagos to progress selected targets into drug discovery — Mechelen, Belgium and Boston, USA; 12 August 2020 –...
PrismRA identifies patients 6.6 times less likely to respond to TNFi therapy JULY 28, 2020- WALTHAM, MA- (Business Wire)- Scipher Medicine, a precision immunology company that helps match patients with their most effective therapy, today announced successful results...
